Published in Neuro Oncol on November 03, 2015
Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. Med Sci Monit (2016) 0.79
Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol (2016) 0.78
Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. AJNR Am J Neuroradiol (2016) 0.75
Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma. Eur Radiol (2017) 0.75
Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma. Neuroradiology (2017) 0.75
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Immortal time bias in pharmaco-epidemiology. Am J Epidemiol (2007) 6.98
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol (2013) 6.19
Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging (1999) 4.94
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68
Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf (2007) 3.66
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol (2009) 2.21
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest (2006) 2.14
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol (2009) 2.08
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol (2011) 2.00
Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology (2006) 1.95
Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys (2007) 1.89
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology (2011) 1.85
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol (2009) 1.83
Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol (2004) 1.69
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol (2001) 1.41
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol (2001) 1.39
Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed (2007) 1.33
Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia (2004) 1.32
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol (2015) 1.26
Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol (2011) 1.24
Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol (2009) 1.21
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol (2015) 1.20
Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology (2012) 1.20
Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol (2012) 1.17
Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15
Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol (2008) 1.15
Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer (2012) 1.05
The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol (2009) 1.04
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol (2015) 1.04
The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives. Cancer Imaging (2014) 1.03
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol (2014) 1.03
Glioma: application of whole-tumor texture analysis of diffusion-weighted imaging for the evaluation of tumor heterogeneity. PLoS One (2014) 1.00
Modern brain tumor imaging. Brain Tumor Res Treat (2015) 0.97
Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol (2011) 0.93
Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Front Oncol (2013) 0.90
Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology (2014) 0.83
Bevacizumab: radiation combination produces restricted diffusion on brain MRI. CNS Oncol (2014) 0.76